AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...

D Molecular Therapeutics (FDMT) stock slips as the company posts early-stage trial data for its cystic fibrosis drug 4D-710.

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5,with follow-up through 1 year at dose selected for Phase 2 Durable ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of ...

EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full ...

(Reuters) - Shares of 4D Molecular Therapeutics more than doubled on Monday after the therapy developer reported results from a mid-stage trial of its eye disease therapy. The stock hit an over ...

EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted ...

The rapid growth of commercial space has unlocked exciting new opportunities for the U.S. federal government. Many of these possibilities lie in the field of geospatial intelligence, or GEOINT, and ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, ...